Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Cash & Current Investments (2016 - 2025)

Anaptysbio (ANAB) has disclosed Cash & Current Investments for 10 consecutive years, with $311.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Current Investments fell 19.13% year-over-year to $311.6 million, compared with a TTM value of $311.6 million through Dec 2025, down 19.13%, and an annual FY2025 reading of $311.6 million, down 19.13% over the prior year.
  • Cash & Current Investments was $311.6 million for Q4 2025 at Anaptysbio, up from $249.0 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $548.1 million in Q4 2021 and bottomed at $249.0 million in Q3 2025.
  • Average Cash & Current Investments over 5 years is $387.2 million, with a median of $390.9 million recorded in 2021.
  • The sharpest move saw Cash & Current Investments surged 77.91% in 2022, then tumbled 42.12% in 2025.
  • Year by year, Cash & Current Investments stood at $548.1 million in 2021, then fell by 19.5% to $441.2 million in 2022, then fell by 11.41% to $390.9 million in 2023, then decreased by 1.41% to $385.4 million in 2024, then decreased by 19.13% to $311.6 million in 2025.
  • Business Quant data shows Cash & Current Investments for ANAB at $311.6 million in Q4 2025, $249.0 million in Q3 2025, and $265.7 million in Q2 2025.